Contribution: Industrial Research Assistance Program – Contributions to Firms
NexPlasmaGen Incorporée
$202,810.00
Validation of a unique high precision Cold Plasma Device for breast cancer treatment – Phase 3
FY 2021-22 · 2021-06-01
Summary
This project will allow to prepare a unique high precision cold plasma device prototype for breast cancer treatment so it can be authorized by Health Canada for an investigational testing (first-in-human) clinical trial.
Department
Program
Industrial Research Assistance Program – Contributions to FirmsIndustrial Research Assistance Program-Contributions to Firms (linked with high confidence)
Recipient
Location
Montreal|Montreal, Quebec, Canada
Recipient Type
For-profit organization
Business Number
819165614
Type
Contribution
Source
Proactive Disclosure - Grants and Contributions
Amendments
Each version of the agreement as published, oldest first, with its total as of that version. The amount above is the latest.
| Amendment | Date | Fiscal Year | Total |
|---|---|---|---|
| 0 | 2021-06-01 | 2021-22 | $120,000.00 |
| 1 | 2021-06-01 | 2021-22 | $136,050.00 |
| 2 | 2021-06-01 | 2021-22 | $136,050.00 |
| 3 | 2021-06-01 | 2021-22 | $136,050.00 |
| 4 | 2021-06-01 | 2021-22 | $175,050.00 |
| 5 | 2021-06-01 | 2021-22 | $202,810.00 |
As published
Additional Information
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 90 days. The total amended value is 27,760 dollars.
Additional Information (French)
Cet accord a été modifié 1 fois La date de fin du présent accord a été changé de 90 jours. La valeur totale des modifications est de 27 760 dollars.
Agreement End Date
2023-03-31
Agreement Number
975628
Agreement Start Date
2021-06-01
Agreement Title
Validation of a unique high precision Cold Plasma Device for breast cancer treatment – Phase 3
Agreement Title (French)
Validation d'un dispositif unique de haute précision à plasma froid pour le traitement du cancer du sein - Phase 3
Agreement Type
Contribution
Agreement Value
$202,810.00
Amendment Date
2022-12-05
Amendment Number
5
Coverage
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation. | Les projets des Contributions aux entreprises stimulent la création de richesse au Canada grâce à l’innovation technologique.
Description
This project will allow to prepare a unique high precision cold plasma device prototype for breast cancer treatment so it can be authorized by Health Canada for an investigational testing (first-in-human) clinical trial.
Description (French)
Ce projet permettra de préparer un prototype unique de dispositif de haute précision à plasma froid pour le traitement du cancer du sein, et ce, afin qu'il puisse être autorisé par Santé Canada pour un essai expérimental (première fois sur l'humain).
Expected Results
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Expected Results (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Federal Riding
Notre-Dame-de-Grâce--Westmount
Federal Riding (French)
Notre-Dame-de-Grâce--Westmount
Federal Riding Number
24053
NAICS Code
339110
Organization Code
nrc-cnrc
Organization
National Research Council Canada | Conseil national de recherches Canada
Program Name
Industrial Research Assistance Program – Contributions to Firms
Program Name (French)
Programme d’aide à la recherche industrielle – Contributions aux entreprises
Program Purpose
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Program Purpose (French)
Le PARI, par le biais des Contributions aux entreprises, vise à appuyer la recherche, le développement, l’adaptation et/ou l’adoption au Canada de produits, de services ou de processus novateurs ou axés sur des technologies nouvelles ou améliorées, et ce jusqu’à leur commercialisation
Recipient Business Number
819165614
Recipient City
Montreal|Montreal
Recipient Country
CA
Recipient Legal Name
NexPlasmaGen Incorporée
Recipient Postal Code
H4A 2T7
Recipient Province or Territory
QC
Recipient Type
F
Reference Number
172-2021-2022-Q2-975628
